Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of AIM ImmunoTech Inc (AMEX: AIM) was $0.12 for the day, down -7.47% from the previous closing price of $0.13. In other words, the price has decreased by -$7.47 from its previous closing price. On the day, 0.94 million shares were traded.
Ratios:
Our analysis of AIM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.75 and its Current Ratio is at 0.75. In the meantime, Its Debt-to-Equity ratio is 1.17 whereas as Long-Term Debt/Eq ratio is at 0.20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 21 ’24 when Equels Thomas K bought 20,000 shares for $0.21 per share. The transaction valued at 4,240 led to the insider holds 1,657,968 shares of the business.
MITCHELL WILLIAM M sold 4,580 shares of AIM for $884 on Dec 19 ’24. The Director now owns 118,549 shares after completing the transaction at $0.19 per share. On Dec 18 ’24, another insider, Equels Thomas K, who serves as the CEO & President of the company, bought 22,727 shares for $0.21 each. As a result, the insider paid 4,682 and bolstered with 1,680,695 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 44.85 while its Price-to-Book (P/B) ratio in mrq is 2.50.
Stock Price History:
Over the past 52 weeks, AIM has reached a high of $0.62, while it has fallen to a 52-week low of $0.12. The 50-Day Moving Average of the stock is -34.28%, while the 200-Day Moving Average is calculated to be -56.61%.
Shares Statistics:
A total of 68.75M shares are outstanding, with a floating share count of 60.91M. Insiders hold about 11.41% of the company’s shares, while institutions hold 6.76% stake in the company.
Earnings Estimates
The current assessment of AIM ImmunoTech Inc (AIM) involves the perspectives of 1.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.09 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.3 and -$0.3 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.37, with 2.0 analysts recommending between -$0.35 and -$0.39.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $100k to a low estimate of $100k. As of the current estimate, AIM ImmunoTech Inc’s year-ago sales were $65k
A total of 1 analysts have provided revenue estimates for AIM’s current fiscal year. The highest revenue estimate was $200k, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $200k. In the same quarter a year ago, actual revenue was $202kBased on 2 analysts’ estimates, the company’s revenue will be $2.6M in the next fiscal year. The high estimate is $5M and the low estimate is $200k.
